Marina Biotech Receives Patent Acceptance Broadly Covering Its Unlocked Nucleobase Analog Technology
News Jan 23, 2012
The company has announced the termination of certain license agreements with Talon Therapeutics, Inc. and Par Pharmaceutical Companies, Inc., relating to the development and commercialization of the Company's ondansetron HCl oral spray product.
Pursuant to the agreements terminating the Talon and Par license agreements, all rights to develop and commercialize the product were returned to the Company in exchange for Talon's right to receive certain royalty payments in connection with the product. The Company believes the termination of these license agreements better positions the Company for a potential strategic transaction by returning control of the product within the United States and Canada to the Company. Further details regarding the terms of the termination agreements can be found in the Company's Current Report on Form 8-K filed in connection herewith.
Targeted Antisense Treatment of APOE4 Reduces Alzheimer's DamageNews
Novel antisense oligonucleotide interferes with the instructions for building the APOE protein and reduces pathophysiology of AD.READ MORE
Lonza, Akouos and MEE Announce Strategic Gene Therapy License Agreements on Hearing and Balance DisordersNews
Lonza and Massachusetts Eye and Ear (MEE) grant Akouos exclusive licenses to proprietary ancestral AAV (Anc-AAV) vectors for all hearing and balance disorders.READ MORE
Maize Pest Exploits Plant Defense Compounds to Protect ItselfNews
Rootworm larvae are able to sequester plant defense compounds from maize roots in a non-toxic form and can activate the toxins whenever they need them to protect themselves against their own enemies.READ MORE